Pfizer's Nurtec ODT (rimegepant) sales figures for 2024 have not yet been publicly released. Companies typically report quarterly and annual financial results after the periods conclude.
When will Pfizer announce Nurtec ODT 2024 sales?
Pfizer is expected to announce its first-quarter 2024 financial results around late April or early May 2024, which will include sales data for its products, including Nurtec ODT. Subsequent quarterly reports will follow throughout the year.
How has Nurtec ODT performed in past sales?
In the full year 2023, Nurtec ODT generated $864 million in net sales for Pfizer [1]. This marked a significant increase from the $733 million reported for 2022 [1].
What is Nurtec ODT used for?
Nurtec ODT is a prescription medication used for the acute treatment of migraine with or without aura and for the preventive treatment of episodic migraine in adults [2]. Rimegepant is the active ingredient in Nurtec ODT [2].
Who manufactures Nurtec ODT?
Pfizer acquired Biohaven Pharmaceutical, the developer of Nurtec ODT, in September 2022 [3]. Therefore, Pfizer is the current manufacturer and marketer of Nurtec ODT.
What is the patent status for Nurtec ODT?
Information on the specific patent expiration dates for Nurtec ODT can be found on DrugPatentWatch.com [4]. Patent exclusivity is a critical factor in the market exclusivity for branded pharmaceuticals and influences the potential entry of generic or biosimilar alternatives.
What are competing treatments for migraine?
The migraine treatment market includes various options, such as other oral medications (triptans, CGRP antagonists), injectable CGRP antagonists, and preventive therapies [2]. Competition for Nurtec ODT includes other drugs in the CGRP antagonist class, both for acute and preventive treatment.
Sources:
[1] Pfizer Inc. (2024). Pfizer Reports Fourth-Quarter and Full-Year 2023 Results. Retrieved from https://investors.pfizer.com/financials/quarterly-results/default.aspx
[2] Nurtec ODT (2023). Nurtec ODT Prescribing Information. Retrieved from https://www.nurtec.com/
[3] Pfizer Inc. (2022, September 12). Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd. Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceutical-holding
[4] DrugPatentWatch.com. (n.d.). Rimegepant Patents. Retrieved from https://drugpatentwatch.com/